Full Text View
Tabular View
No Study Results Posted
Related Studies
Characteristics of Prader-Willi Syndrome and Early-onset Morbid Obesity
This study is currently recruiting participants.
Verified November 2011 by University of Florida

First Received on September 11, 2006.   Last Updated on November 8, 2011   History of Changes
Sponsor: University of Florida
Collaborators: Office of Rare Diseases (ORD)
Rare Diseases Clinical Research Network
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Information provided by (Responsible Party): University of Florida
ClinicalTrials.gov Identifier: NCT00375089
  Purpose

Prader-Willi syndrome (PWS) is a rare genetic disorder that affects about 1 in 14,000 people in the United States. As the most commonly identified genetic cause of obesity, PWS is often confused with Early-onset Morbid Obesity (EMO). Individuals with EMO show some signs of PWS, but clinically do not have PWS. The purpose of this study is to evaluate the clinical features and genetic basis of PWS and EMO, and to determine how these conditions affect a person throughout a lifetime.


Condition
Prader-Willi Syndrome
Obesity

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Prader-Willi Syndrome and Early-onset Morbid Obesity Natural History Clinical Protocol

Resource links provided by NLM:


Further study details as provided by University of Florida:

Biospecimen Retention:   Samples With DNA

Blood samples for both DNA and RNA


Estimated Enrollment: 300
Study Start Date: September 2006
Estimated Study Completion Date: July 2014
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Individuals with Prader-Willi syndrome
2
Individuals with Early-onset Morbid Obesity

Detailed Description:

PWS is a complex neurobehavioral syndrome. Clinical features include obesity, increased appetite, low muscle tone, cognitive impairment, distinct behavioral features, hypogonadism, and neonatal failure-to-thrive. It is the most commonly recognized genetic cause of obesity; however, many obese children do not in fact have PWS. These individuals are therefore diagnosed with EMO, a condition that shares features with PWS. The development of new advances and strategies for treating PWS and EMO requires a thorough understanding of the conditions at both the clinical and molecular levels. One goal of this study is to collect long-term data on individuals with PWS and EMO in order to gain a better understanding of the natural progression of the conditions, from the neonatal period well into adulthood. Specific to PWS, this study will establish a genotype-phenotype correlation among the different sub-types and will evaluate the effects of growth hormone treatment on disease progression. Lastly, the study will compare PWS with EMO in terms of clinical features and genetic basis.

Participation in this natural history study will entail an initial evaluation, followed by yearly study visits until the age of 3 and then every 2 years thereafter. Each study visit will last between 3 and 4 hours, and will include a physical exam (including a DEXA scan to determine body composition), psychological testing, an interview with the study physician, and an evaluation of the participant's diet history. In addition, blood tests will be completed for genetic testing and photos will be taken to evaluate disease progression. Cognitive and behavioral assessments will also be conducted and will last between 10 and 30 minutes.

  Eligibility

Ages Eligible for Study:   up to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Individuals with Prader-Willi syndrome and Early-onset Morbid Obesity

Criteria

Inclusion Criteria:

  • Individuals enrolling in the Prader-Willi syndrome group will have a confirmed diagnosis of Prader-Willi syndrome, as confirmed by molecular and cytogenetic testing
  • Individuals enrolling in the Early-onset Morbid Obesity group will have a documented medical history of their weight exceeding 150% of the ideal body weight or a body mass index greater than 97% before the age of 4 years; they will also be under the age of 30 years.

Exclusion Criteria:

  • Known genetic, chromosomal, or hormonal cause of cognitive impairment other than Prader-Willi syndrome
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00375089

Locations
United States, California
University of California at Irvine Recruiting
Orange, California, United States, 92868
Contact: Virginia Kimonis, MD     714-456-5791     vkimonis@uci.edu    
Principal Investigator: Virginia Kimonis, MD            
United States, Florida
University of Florida Recruiting
Gainesville, Florida, United States, 32610-0296
Contact: Daniel J. Driscoll, PhD, MD     352-392-4104     driscdj@peds.ufl.edu    
Principal Investigator: Daniel J. Driscoll, PhD, MD            
Principal Investigator: Jennifer Miller, MD            
United States, Kansas
Kansas University Medical Center Recruiting
Kansas City, Kansas, United States, 66160
Contact: Merlin G. Butler, MD, PhD, FFACMG     913-588-1800     mbutler4@kumc.edu    
Principal Investigator: Merlin G. Butler, PhD, MD            
United States, Tennessee
Vanderbilt University Medical Center Recruiting
Nashville, Tennessee, United States
Contact: Elizabeth Roof, MA     615-343-3330     elizabeth.roof@vanderbilt.edu    
Principal Investigator: Marshall L. Summar, MD            
Sponsors and Collaborators
University of Florida
Rare Diseases Clinical Research Network
Investigators
Study Chair: Arthur Beaudet, MD Baylor College of Medicine
  More Information

Publications:
Miller J, Kranzler J, Liu Y, Schmalfuss I, Theriaque DW, Shuster JJ, Hatfield A, Mueller OT, Goldstone AP, Sahoo T, Beaudet AL, Driscoll DJ. Neurocognitive findings in Prader-Willi syndrome and early-onset morbid obesity. J Pediatr. 2006 Aug;149(2):192-8.
Miller JL, Couch JA, Schmalfuss I, He G, Liu Y, Driscoll DJ. Intracranial abnormalities detected by three-dimensional magnetic resonance imaging in Prader-Willi syndrome. Am J Med Genet A. 2007 Mar 1;143(5):476-83.
Butler MG. Management of obesity in Prader-Willi syndrome. Nat Clin Pract Endocrinol Metab. 2006 Nov;2(11):592-3. No abstract available.
Butler MG, Bittel DC, Kibiryeva N, Talebizadeh Z, Thompson T. Behavioral differences among subjects with Prader-Willi syndrome and type I or type II deletion and maternal disomy. Pediatrics. 2004 Mar;113(3 Pt 1):565-73.
Dykens E, Shah B. Psychiatric disorders in Prader-Willi syndrome: epidemiology and management. CNS Drugs. 2003;17(3):167-78. Review.
Goldstone AP. Prader-Willi syndrome: advances in genetics, pathophysiology and treatment. Trends Endocrinol Metab. 2004 Jan-Feb;15(1):12-20. Review.
Miller J, Silverstein J, Shuster J, Driscoll DJ, Wagner M. Short-term effects of growth hormone on sleep abnormalities in Prader-Willi syndrome. J Clin Endocrinol Metab. 2006 Feb;91(2):413-7. Epub 2005 Nov 29.
Shapira NA, Lessig MC, He AG, James GA, Driscoll DJ, Liu Y. Satiety dysfunction in Prader-Willi syndrome demonstrated by fMRI. J Neurol Neurosurg Psychiatry. 2005 Feb;76(2):260-2.
Bittel DC, Butler MG. Prader-Willi syndrome: clinical genetics, cytogenetics and molecular biology. Expert Rev Mol Med. 2005 Jul 25;7(14):1-20.
Holsen LM, Zarcone JR, Brooks WM, Butler MG, Thompson TI, Ahluwalia JS, Nollen NL, Savage CR. Neural mechanisms underlying hyperphagia in Prader-Willi syndrome. Obesity (Silver Spring). 2006 Jun;14(6):1028-37.
Cassidy SB, Driscoll DJ. Prader-Willi syndrome. Eur J Hum Genet. 2008 Sep 10; [Epub ahead of print]

Responsible Party: University of Florida
ClinicalTrials.gov Identifier: NCT00375089     History of Changes
Other Study ID Numbers: RDCRN 5202, U54HD061222, ARP 5202
Study First Received: September 11, 2006
Last Updated: November 8, 2011
Health Authority: United States: Federal Government

Keywords provided by University of Florida:
Early-onset Morbid Obesity

Additional relevant MeSH terms:
Obesity
Obesity, Morbid
Prader-Willi Syndrome
Overnutrition
Nutrition Disorders
Overweight
Body Weight
Signs and Symptoms
Mental Retardation
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Abnormalities, Multiple
Congenital Abnormalities
Chromosome Disorders
Genetic Diseases, Inborn

ClinicalTrials.gov processed this record on February 09, 2012